Cancer Immunotherapy

Cancer Immunotherapy

Global Cancer Immunotherapy Market to Reach US$378.5 Billion by 2030

The global market for Cancer Immunotherapy estimated at US$155.2 Billion in the year 2023, is expected to reach US$378.5 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2023-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.4% CAGR and reach US$266.2 Billion by the end of the analysis period. Growth in the Cytokines & Immunomodulators segment is estimated at 12.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$40.1 Billion While China is Forecast to Grow at 17.7% CAGR

The Cancer Immunotherapy market in the U.S. is estimated at US$40.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$94.0 Billion by the year 2030 trailing a CAGR of 17.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Global Cancer Immunotherapy Market – Key Trends & Drivers Summarized

Why Is Cancer Immunotherapy Gaining Momentum in Oncology?

Cancer immunotherapy has emerged as one of the most promising and transformative treatment modalities in oncology, revolutionizing how cancer is treated. Unlike traditional therapies such as chemotherapy and radiation, which target cancer cells directly, immunotherapy harnesses the body’s immune system to recognize and attack cancer cells. This approach has shown remarkable efficacy in treating several types of cancer, including melanoma, lung cancer, and certain types of blood cancers. The ability of immunotherapy to provide durable responses, sometimes leading to complete remission, even in late-stage cancers, has made it a game-changing treatment option. Immunotherapy drugs, such as checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies, are being increasingly integrated into standard cancer treatment protocols, providing new hope to patients who may not respond well to conventional therapies.

The success of immunotherapy is also attributed to its potential for long-term cancer control. For some patients, immunotherapy has shown the ability to provide lasting protection by creating an immune memory that can continue to recognize and destroy cancer cells even after treatment has ended. This durability sets it apart from many traditional treatments that often need continuous administration. With increasing clinical success and a growing number of immunotherapy drugs receiving regulatory approvals, this approach is rapidly becoming a cornerstone of cancer treatment across the globe.

How Are Technological Advancements and New Discoveries Shaping the Immunotherapy Landscape?

Technological advancements and groundbreaking discoveries are significantly expanding the capabilities of cancer immunotherapy. One of the most significant developments has been the rise of checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, which work by blocking proteins that prevent the immune system from attacking cancer cells. These drugs have become a standard treatment for cancers like melanoma and non-small cell lung cancer, among others, and are now being tested in combination with other therapies to enhance their effectiveness. The development of personalized immunotherapies, particularly CAR-T cell therapy, which involves engineering a patient’s own T-cells to target and kill cancer cells, has also generated a great deal of excitement. CAR-T therapy has demonstrated extraordinary success in treating certain blood cancers, particularly in patients who have exhausted other treatment options.

Emerging technologies like artificial intelligence (AI) and machine learning are playing an increasingly important role in accelerating immunotherapy research. AI is being used to analyze vast datasets to identify new biomarkers and predict patient responses to immunotherapy, improving personalized treatment strategies. Advancements in gene editing tools like CRISPR are also being explored to enhance the effectiveness of T-cell therapies and develop next-generation immunotherapies. Additionally, research into cancer vaccines and oncolytic viruses—viruses that can infect and kill cancer cells—shows promising potential to further expand the immunotherapy toolkit. These innovations are expected to push the boundaries of what immunotherapy can achieve, potentially unlocking new treatments for cancers that have been historically difficult to treat.

How Are Changing Consumer Preferences and Healthcare Trends Impacting Immunotherapy Demand?

The rising demand for more effective, less toxic cancer treatments is driving the adoption of immunotherapy across various healthcare settings. Patients today are more informed about their treatment options and increasingly seek therapies that offer fewer side effects compared to traditional treatments like chemotherapy, which is known for its harsh adverse effects such as fatigue, nausea, and immune suppression. Immunotherapy is often better tolerated, with many patients experiencing fewer or less severe side effects, making it an attractive option for those seeking a higher quality of life during treatment. This shift in patient preferences toward targeted, less invasive therapies is accelerating the adoption of immunotherapies.

Moreover, immunotherapy is becoming more accessible, thanks to the growing number of approved drugs and expanded indications for existing treatments. Immunotherapies that were initially approved for a narrow range of cancers are now being explored and authorized for use in other cancer types, creating broader treatment opportunities. The rising demand for personalized medicine is another significant factor influencing the market, as patients and healthcare providers increasingly seek tailored treatments that are specific to an individual’s genetic makeup or tumor profile. As immunotherapy often requires biomarker testing to identify eligible patients, it aligns well with the trend toward personalized cancer care, further driving its uptake in oncology practices worldwide.

Growth in the Cancer Immunotherapy Market Is Driven by Several Factors

The growth in the cancer immunotherapy market is driven by several factors, including advancements in drug development, increasing prevalence of cancer, and the rising demand for personalized and targeted treatments. Technological breakthroughs, particularly in the development of checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines, have opened new avenues for treating both solid tumors and hematologic cancers. The success of these therapies in achieving durable responses and even long-term remission in some patients has fueled further research and investment in the field. Additionally, the ongoing expansion of approved immunotherapies to treat a wider range of cancers is contributing to market growth, as more patients become eligible for these innovative treatments.

Another key driver is the increasing focus on combination therapies, where immunotherapy is used alongside chemotherapy, radiation, or other targeted therapies to enhance treatment efficacy. This approach is showing promising results in clinical trials, as combining therapies can help overcome resistance and improve patient outcomes. The rise in biomarker-based diagnostics is also playing a significant role, as it enables oncologists to identify which patients are most likely to benefit from immunotherapy, thus optimizing treatment selection and improving success rates. Furthermore, the growing investment in research and development, both by pharmaceutical companies and academic institutions, is accelerating the discovery of new immunotherapies and expanding the market’s potential. As these trends continue to evolve, the cancer immunotherapy market is poised for robust growth, offering new hope for cancer patients worldwide.

Select Competitors (Total 42 Featured) -

• Advaxis Inc.
• Amgen Inc.
• Astrazeneca
• Bayer AG
• Bristol-Myers Squibb
• Celgene Corporation
• ELI Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Immunomedics Inc.
• Janssen Global Services, LLC (Johnson and Johnson)
• Merck
• Novartis
• Pfizer
• Seattle Genetics, Inc.
• Spectrum Pharmaceuticals, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.